Cargando…
2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age
BACKGROUND: Influenza virus infection in the elderly remains one of the ten leading causes of death. One successful strategy to enhance the magnitude of their influenza vaccine immune response has been the addition of the adjuvant MF59(®). METHODS: 196 subjects ≥ 65 years of age were enrolled in a d...
Autores principales: | Otten, Gillis, Matassa, Vince, Ciarlet, Max, Leav, Brett |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255289/ http://dx.doi.org/10.1093/ofid/ofy210.2142 |
Ejemplares similares
-
1435. The Cost-Effectiveness of Vaccinating With an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina
por: Nguyen, Van, et al.
Publicado: (2018) -
987. Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study
por: Daly, Wendy, et al.
Publicado: (2018) -
Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection
por: Sanchez Alberti, Andrés, et al.
Publicado: (2017) -
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
por: Li, Rongcheng, et al.
Publicado: (2008) -
Adjuvants Differentially Modulate the Immunogenicity of Lassa Virus Glycoprotein Subunits in Mice
por: To, Albert, et al.
Publicado: (2022)